Genprex to Present at Upcoming Investor Conferences

AUSTIN, Texas & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today that company management will present at the following upcoming investor and industry conferences:

About Genprex, Inc.Genprex, Inc. is a clinical stage gene therapy company developing a new approach to treating cancer, based upon a novel proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. Oncoprex has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance. Visit the company’s web site at www.genprex.com or follow Genprex on Twitter at https://twitter.com/genprex and Facebook at https://www.facebook.com/genprexinc/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180821005237/en/

Media:
ICR Healthcare
James Heins, 203-682-8251
[email protected]
or
Investors:
ICR Healthcare
Stephanie Carrington, 646-277-1282
[email protected]

Source: Genprex, Inc.

You May Also Be Interested In

• Chainlink Price Prediction Points to Growth as Pepeto Builds an Early Window Below a Cent
• 30-Year Selbyville DE Firm Offers Custom Sunrooms & Porch Enclosures
• Florida Contractor Expands Private Inspections for Storm Roof Work